Sgrignani, J.; ICRM-CNR, Via Mario Bianco 9, Milan, 20131, Italy, Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), Via Vincenzo Vela 6, Bellinzona, 6500, Switzerland
De Luca, F.; Dipartimento di Biotecnologie Mediche, Università di Siena, Policlinico “Le Scotte”, Viale Bracci 16, Siena, 53100, Italy
Torosyan, H.; Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 Fourth Street, Byers Hall, San Francisco, CA 94158, United States
Docquier, Jean-Denis ; Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines
Duan, D.; Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 Fourth Street, Byers Hall, San Francisco, CA 94158, United States
Novati, B.; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25, Milan, 20133, Italy
Prati, F.; Dipartimento di Scienze della Vita, Università di Modena e Reggio Emilia, Via G. Campi 103, Modena, 41125, Italy
Colombo, G.; ICRM-CNR, Via Mario Bianco 9, Milan, 20131, Italy
Grazioso, G.; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25, Milan, 20133, Italy
Language :
English
Title :
Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors
Publication date :
2016
Journal title :
Journal of Computer-Aided Molecular Design
ISSN :
0920-654X
eISSN :
1573-4951
Publisher :
Springer International Publishing
Volume :
30
Issue :
10
Pages :
851-861
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Regione Lombardia AIRC - Associazione Italiana per la Ricerca sul Cancro
Drawz SM, Bonomo RA (2010) Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23(20065329):160–201
Drawz SM, Papp-Wallace KM, Bonomo RA (2014) New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835–1846
Farina D, Spyrakis F, Venturelli A, Cross S, Tondi D, Costi MP (2014) Curr Med Chem 21:1405–1434
Ambler RP (1980) Philos Trans R Soc Lond Ser B Biol Sci 289:321–331
Prestinaci F, Pezzotti P, Pantosti A (2015) Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109:309–318
Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N (2008) NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 62:1053–1056
Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757
Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN (2015) Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682–3692
Livermore DM, Warner M, Mushtaq S (2013) Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290
https://clinicaltrials.gov/ct2/show/NCT01897779
Weston GS, Blazquez J, Baquero F, Shoichet BK (1998) Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. J Med Chem 41:4577–4586
Tondi D, Venturelli A, Bonnet R, Pozzi C, Shoichet BK, Costi MP (2014) Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. J Med Chem 57:5449–5458
Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F (2003) Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc 125:685–695
Eidam O, Romagnoli C, Dalmasso G, Barelier S, Caselli E, Bonnet R, Shoichet BK, Prati F (2012) Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proc Natl Acad Sci USA 109:17448–17453
Wang X, Minasov G, Blazquez J, Caselli E, Prati F, Shoichet BK (2003) Recognition and resistance in TEM beta-lactamase. Biochemistry 42:8434–8444
London N, Miller RM, Krishnan S, Uchida K, Irwin JJ, Eidam O, Gibold L, Cimermancic P, Bonnet R, Shoichet BK, Taunton J (2014) Covalent docking of large libraries for the discovery of chemical probes. Nat Chem Biol 10:1066–1072
Sgrignani J, Novati B, Colombo G, Grazioso G (2015) Covalent docking of selected boron-based serine beta-lactamase inhibitors. J Comput Aided Mol Des 29:441–450
Beesley T, Gascoyne N, Knott-Hunziker V, Petursson S, Waley SG, Jaurin B, Grundström T (1983) The inhibition of class C β-lactamases by boronic acids. Biochem J 209:229–233
Tondi D, Calò S, Shoichet BK, Costi MP (2010) Structural study of phenyl boronic acid derivatives as AmpC β-lactamase inhibitors. Bioorg Med Chem Lett 20:3416–3419
Dubus A, Normark S, Kania M, Page MG (1995) Role of asparagine 152 in catalysis of beta-lactam hydrolysis by Escherichia coli AmpC beta-lactamase studied by site-directed mutagenesis. Biochemistry 34:7757–7764
Powers RA, Shoichet BK (2002) Structure-based approach for binding site identification on AmpC beta-lactamase. J Med Chem 45:3222–3234
Ruble JF, Lefurgy ST, Cornish VW, Powers RA (2012) Structural analysis of the Asn152Gly mutant of P99 cephalosporinase. Acta Crystallogr D 68:1189–1193
Ke W, Bethel CR, Papp-Wallace KM, Pagadala SR, Nottingham M, Fernandez D, Buynak JD, Bonomo RA, van den Akker F (2012) Crystal structures of KPC-2 beta-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrob Agents Chemother 56:2713–2718
Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748
Hartshorn MJ, Verdonk ML, Chessari G, Brewerton SC, Mooij WT, Mortenson PN, Murray CW (2007) Diverse, high-quality test set for the validation of protein-ligand docking performance. J Med Chem 50:726–741
Clark M, Cramer RD, Van Opdenbosch N (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982–1012
Korb O, Stutzle T, Exner TE (2009) Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Mod 49:84–96
Johnson SC (1967) Hierarchical clustering schemes. Psychometrika 32:241–254
Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD (2010) Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. Antimicrob Agents Chemother 54:3197–3204
De Luca F, Benvenuti M, Carboni F, Pozzi C, Rossolini GM, Mangani S, Docquier JD (2011) Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. Proc Natl Acad Sci USA 108:18424–18429
De Luca F, Rossolini GM, Docquier JD (2015) In: ASM Press (ed) 55th Interscience conference on antimicrobial agents and chemotherapy, ICAAC/ICC 2015. Washington DC, San Diego, CA
Docquier JD, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L, Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S (2009) Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 16:540–547
Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, Docquier JD (2013) Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 57:2496–2505
Docquier JD, Pantanella F, Giuliani F, Thaller MC, Amicosante G, Galleni M, Frere JM, Bush K, Rossolini GM (2002) CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother 46:1823–1830
Docquier JD, Lamotte-Brasseur J, Galleni M, Amicosante G, Frere JM, Rossolini GM (2003) On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother 51:257–266
